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Summary

We conducted a systematic review of the treatment, prevention and public health control of skin
infections including impetigo, scabies, crusted scabies and tinea in resource-limited settings where
skin infections are endemic. The aim is to inform strategies, guidelines and research to improve skin
health in populations that are inequitably affected by infections of the skin and the downstream
consequences of these. The systematic review is reported according to the PRISMA statement. From
1759 titles identified, 81 full text studies were reviewed and key findings outlined for impetigo,
scabies, crusted scabies and tinea. Improvements in primary care and public health management of
skin infections will have broad and lasting impacts on overall quality of life including reductions in
morbidity and mortality from sepsis, skeletal infections, kidney and heart disease.
keywords impetigo, scabies, crusted scabies, tinea

Introduction
Children in developing countries and other resource-limited settings bear a disproportionate burden of skin infections, owing to poverty, poorer living conditions,
normalisation and limited access to primary healthcare
[1–4]. More than 162 million children are estimated to
have impetigo at any one time [5] and more than 110
million children with scabies [6]. There are no estimates
for the global burden of tinea in children, although fungal skin infections were the leading skin disease and
placed in the top 10 most prevalent diseases worldwide
in 2010 [7].
Primary infection with impetigo and secondary bacterial infection of scabies, crusted scabies and tinea with
280

the bacteria Staphylococcus aureus and Streptococcus
pyogenes (Group A Streptococcus, GAS) lead to morbidity, mortality and socioeconomic costs via invasive infection [8, 9]. Invasive S. aureus has a global incidence
estimate of 20–50 cases/100 000 population per year
with a case fatality rate of 5–30% [10, 11]. An estimated
163 000 people die from GAS bacteraemia each year [8].
Moreover, post-streptococcal sequelae of acute rheumatic
fever (ARF) and acute post-streptococcal glomerulonephritis (APSGN) can lead to long-term consequences
of chronic heart and kidney disease [8, 12, 13]. Due to
differences in the social determinants of health, there
exists a marked disparity in the burden of skin infections
and their sequelae between resource-rich and resourcelimited settings [14].

© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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Systematic reviews of skin infection treatments that
have only included randomised clinical trials (RCT)
[15–18], exclude a large body of available evidence
from resource-limited settings where the burden is
highest [5–7]. RCTs are often conducted in hospital
outpatient departments (OPD) in high-income settings,
and findings may not be directly applicable to resourcelimited settings where cultural practices, access, availability, cost and acceptability of treatments may differ.
There remains a lack of consensus on the best treatments and population health approaches for the prevention and control of skin infections, both individual
skin conditions and skin infections collectively, in these
resource-limited settings due to a lack of a review of
the evidence that is externally valid to these populations. We conducted a systematic review of studies
from resource-limited and endemic settings regarding
the prevention, treatment and public health management of impetigo, scabies, crusted scabies and tinea to
inform the development of evidence-based guidelines
and future research priorities for skin infections in
endemic populations.

Methods
Search strategy and selection criteria
This systematic review is reported according to the
Preferred Reporting items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [19]. The methods
and search strategy have been described previously
[20]. Briefly peer reviewed and grey literature databases were searched. Studies published in English since
1960 using any experimental study (RCTs, clinical
controlled trials, before and after studies and interrupted time series analyses) or observational study
design (cohort and ecological studies) were included.
Eligible participant types included Indigenous peoples
and populations in resource-limited settings (low, lowmiddle and middle-income countries and resource-limited populations in Organisation for Economic Cooperation and Development (OECD) countries) (see
Appendix S1 for definitions) with a diagnosis of impetigo, scabies, crusted scabies, tinea capitis, tinea corporis or tinea unguium (onychomycosis) in persons of
any age or sex. We reviewed any clinical or public
health interventions aiming to reduce skin infections
with any type of comparator. Outcomes were categorised as primary (cure or decrease in prevalence for
population-based studies) or secondary (microbiological cure, symptom relief, recurrence, adherence,
acceptability, adverse events and spread to contacts).

Two authors (AB and PM) independently screened the
titles and abstracts of all studies identified in the
search process and selected the studies for eligibility
assessment. Full reports of these studies were obtained
and assessed by two independent reviewers (10 reviewers in total). Any discrepancies for inclusion were
resolved by consensus discussion.
Assessment of methodological quality and data extraction
Two reviewers independently scored for methodological
quality of clinical trials using The Cochrane Collaboration’s tool for assessing risk of bias [21]. Observational
studies were assessed for blinding, completeness of outcome data, outcome reporting and other sources of bias
including confounders. All data were entered into data
extraction forms using Covidence online software (Veritas Health Innovation, Melbourne, VIC, Australia) by the
two independent reviewers and discrepancies resolved via
discussion.
Statistical analysis and synthesis
The data are presented in a narrative synthesis. Metaanalysis was not performed due to the heterogeneity of
studies. Calculations were performed using STATA13
(Statacorp, Texas, USA). For reading ease, results are
presented in common theme groups in each area of
clinical treatment or public health prevention and control relevant to skin infections in resource-limited settings. As many population-based studies incorporate
multiple strategies such as health education, treatment
and hygiene practices, it is recommended that all evidence is considered by the reader as a whole. We used
the GRADE approach to rate evidence across studies
for specific clinical outcomes to link evidence-quality
evaluations to recommendations in clinical guidelines
(Table 1).
Results
The search strategy identified 1759 titles and 455
abstracts for screening, of which 193 met the inclusion
criteria. 81 full text studies were included (Figure 1), representing >27 633 participants over a 40-year period
(1976–2015). The study size, type, location and condition
under study are summarised (Figure 2, Table S1). The
study details and characteristics are summarised in
Table 2. There were 44 (54%) RCTs, four (5%) cluster
RCTs, three (4%) controlled clinical trials, three (4%)
controlled before and after studies and three (4%) controlled population studies (Table S2). There were two

© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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Table 1 Grading of recommendations assessment, development and evaluation evidence grades and strength of recommendations

Code

Quality of
evidence

A

High

B

Moderate

C

Low

D

Very Low

Code

Strength of
recommendation

1

Strong

2

Weak

Definition
Further research is very unlikely to change the level of confidence in the estimate of effect. i.e.
• Several high-quality studies with consistent results
Further research is likely to have an impact in current confidence in the estimate of effect and may
change the estimate. i.e.
• One high-quality study
• Several studies with some limitations
Further research is very likely to have an important impact on the level of confidence in the estimate of
effect and would likely change the estimate. i.e.
• One or more studies with severe limitations
Estimate of effect is very uncertain. i.e.
• No direct research evidence
• One of more studies with very severe limitations
Implications when combined with evidence grade
1A: Strong recommendation, applies to most patients without reservation. Clinicians should follow a
strong recommendation unless a clear and compelling rationale for an alternative approach is present.
1B: Strong recommendation, applies to most patients. Clinicians should follow a strong recommendation
unless a clear and compelling rationale for an alternative approach is present.
1C: Strong recommendation, applies to most patients. Some of the evidence base supporting the
recommendation is, however, of low quality.
1D: * Strong recommendation, applies to most patients. However, the recommendation is based on
expert consensus only.
2A: Weak recommendation and best action may differ depending on circumstances or patients or
societal values.
2B: Weak recommendation and alternative approaches likely to be better for some patients under
some circumstances.
2C: Very weak recommendation; other alternatives may be equally reasonable.
2D: * Very weak recommendation based on expert consensus. Further research is necessary.

*1D and 2D recommendations are not routinely included by the GRADE approach as these are based on expert consensus, rather than
scientific evidence. These additional recommendation grades were created due to lack of available supporting evidence but an identified
need to make recommendations to guide clinical and public health management.

(3%) before and after studies, four (5%) ecological
studies, 14 (17%) prospective cohort studies and four
(5%) retrospective observational studies appraised
(Table S3).
Summary of clinical treatment recommendations for
resource-limited settings
Comprehensive community skin health programmes. Moderate quality evidence that treatment combined with comprehensive skin control measures (health
promotion, environmental interventions and screening)
add benefit in sustaining a reduction in scabies prevalence
alone (2B) [22] and impetigo and scabies prevalence combined (2C) (Appendix S2) [23–25]. No studies assessed the
effect of a community skin health programme on impetigo
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or tinea alone, whilst one study described this for scabies
[22], one for scabies and impetigo [23, 24], and one for
general skin infections [25]. High-quality evidence from
studies using control communities would be advantageous
in determining the measurable benefit over standard treatment (Table 3).
In Bangladesh, moderate quality evidence was provided from a study where permethrin Mass Drug
Administration (MDA) was followed by randomisation
of male boarding school students to a scabies control
programme (repeat permethrin treatment for scabies,
health promotion activities with a designated scabies
class monitor, daily bathing with soap and bags for
bedding and clothing storage) or control [22]. At
4 months, scabies prevalence was 5% (intervention)
and 50% (control), P < 0.001 [22]. In Australia, low-

© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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Identification

Records identified through database

Additional records identified through

searching (n = 3647)

other sources (n = 8)

Records after duplicates removed

(n = 1893)

Eligibility

Screening

(n = 1759)

Included

Duplicates

Titles screened

Records excluded

(n = 1759)

(n = 1304)

Abstracts screened

Records excluded

(n = 455)

(n = 262)

Full-text articles excluded
Full-text articles assessed

(n = 112)

for eligibility (n = 193)

Reasons:
No intervention/no assessment
of effect of exposure on the
outcome (n = 31)
Wrong study design (n = 27)
Not in English (n = 19)
Unable to obtain full-text (n = 8)
Wrong outcomes (n = 8)
Wrong patient population (n = 9)
Wrong setting (n = 4)
Duplicate report of published
paper (n = 3)
Wrong indication (n = 1)

Studies included
(n = 81)

Figure 1 PRISMA flow diagram for study selection in the systematic review.

quality evidence was provided from a permethrin
MDA that included a comprehensive skin control programme (annual treatment and community clean up
days, health promotion and repeat treatment with permethrin for scabies) in a remote Indigenous community [23, 24]. Scabies prevalence declined from 35% to
12%, P < 0.0001 and impetigo from 11% to 2%,
P = 0.0005 [23, 24]. In Kenya, low-quality evidence
was provided from a 5-year dermatology project

within primary healthcare (training of healthcare workers and school-based treatments) that did not show a
sustained reduction in impetigo, scabies or tinea [25].
Impetigo. Directed antimicrobial therapy. High-quality
evidence supports the use of oral co-trimoxazole or intramuscular (IM) benzathine penicillin G (BPG) for the
treatment of impetigo (1A) [26, 27]. Oral amoxicillin or
oral erythromycin are suitable alternatives (2B) [28]. Oral

© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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Figure 2 Selected summary
characteristics of studies included in the
systematic review. [Colour figure can be
viewed at wileyonlinelibrary.com].

Table 2 Number of studies in each broad intervention group by skin condition. Gaps in the evidence are shown as grey boxes
Condition

Intervention
Comprehensive community
skin health programmes
Coordinated case management
Standard treatment protocols
Directed clinical treatment
Mass Drug Administration
Complimentary/
alternative therapy
Communicable
disease control*
Hygiene practices‡
Water provision†
Housing programmes
Total

Impetigo

Scabies
1

4

19
4
2

Scabies and
impetigo

Crusted
scabies

Fungal skin
infections

1
1
1
1

Multiple skin conditions under
study or ‘skin infections’
that were not otherwise
specified
1

3

1

1
1
47
13
4

23

9
1

3
2
1
7

3
1
1

29

Total
number
of studies

11

3

25

2
2
6

3
4
2
81

*Communicable disease control activities= outbreak response or treatment of contacts.
†Water provision = swimming pools or clean water supply to homes.
‡Hygiene practices = provision of soap and hand-washing education.

penicillin G is not recommended for treatment of impetigo (2D) [29]. Although topical antibiotics are recommended as the preferred treatment for impetigo in
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industrialised settings [16], there is no available evidence
from resource-limited contexts for topical antibiotics or
evidence to not treat impetigo.

© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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Table 3 Number of included studies with public health co-interventions for skin infections

Skin condition
Impetigo
Scabies
Scabies and
impetigo
Crusted scabies
Fungal skin
infections
General skin
infections
Total

Public health
co-interventions

Treatment
of contacts

Promotion of
regular bathing
and/or
hand-washing

2
22
5

14
1

2
2
1

Health
education
1
6
3

1

1

4

2

2

8

12

34

15

Washing of
clothing and
bed linen

Storage of
items in
plastic bags

Exposing
items to
direct sunlight

Household
spraying

12
2

2

4
1

1
1

14

2

5

2

*Total does not equate to 81 studies as some studies had more than one public health intervention.
Grey shades represent missing data i.e., nothing known for these categories.

High-quality evidence from two open label RCTs
with Australian Indigenous children compared oral cotrimoxazole vs. IM BPG and found no difference in
clinical or microbiological cure of impetigo [26, 27].
Moderate quality RCT evidence reported clinical cure
in 89% of patients in both groups when oral amoxicillin and oral erythromycin for 7 days in Mali were
compared [28]. Low-quality RCT evidence in Canadian
Indigenous children compared oral penicillin G for
10 days with IM BPG, with treatment failure equivalent: 16% and 14% respectively [29]. No studies
assessed topical agents or used a placebo-controlled
design for impetigo.
Mass Drug Administration. No studies assessed MDA
for impetigo alone. Impetigo was a secondary outcome in
scabies MDAs reported below.
Complimentary/alternative therapies. No studies assessed
complimentary therapies for impetigo.
Hand-washing and hygiene practices. High-quality evidence supports daily hand-washing with soap for the treatment and prevention of impetigo, with no benefit found
for antibacterial soap over regular soap (1A) [30, 31].
In Pakistan, high-quality evidence from two RCTs
enrolling households with children assessed hand-washing
with soap for impetigo and found a benefit for soap, but
no difference between antibacterial (triclocarbon 1.2%)
and standard soap [30, 31].
Scabies. All studies on scabies treatment used clinical
cure or symptom relief as end points.

Directed anti-parasitic therapy. Topical treatment vs.
topical treatment—Seven studies compared topical antiparasitic agents for scabies [32–38], with low to moderate quality evidence for either topical permethrin or
topical ivermectin (2B) [32, 33]. Permethrin is superior
to lindane (1A) [34], topical crotamiton (2C)[35] or
Tenutex emulsion (disulphiram and benzyl benzoate [BB]) in those >4 years (2C) [36]. Topical ivermectin is superior to topical crotamiton in those
>2 years (2C) [37]. Very low-quality evidence from one
study shows that topical BB or topical permethrin
is safe in pregnant women (2C) [38]. Without
high-quality evidence to support modified applications of topical treatments for scabies, the standard whole-body application remains strongly
recommended (1D).
High-quality RCT evidence from an Iranian hospital
OPD found that two applications of 5% permethrin
achieved a superior clinical cure (85%) compared to
1% lindane (49%), P < 0.05 [34]. Clinical cure was
similar with topical ivermectin or topical permethrin in
an Iranian dermatology OPD [33]. When topical ivermectin 1% and topical permethrin 5% were compared
with oral ivermectin, clinical response at 1 week was
superior with either topical treatment (69% and 75%
vs. 30%, P < 0.05) whilst cure at 4 weeks was universal for all three agents [32]. Topical permethrin [35]
and topical ivermectin [37] were superior to topical
crotamiton at 4 weeks follow-up. Topical permethrin
was superior to Tenutex emulsion [36]. Very low-quality evidence from a refugee camp on the Thai-Burmese
border assessed safety of permethrin and BB in pregnancy [38].

© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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Modified application of permethrin
Practice point Box: How is it best to apply topical
scabicides?
Twenty-nine studies incorporated a topical scabicide/s, mostly permethrin. (Table S4). One study
directly compared neck to toe application (head to
toe in children) with application to lesions only
[39]. Overall, head to toe or neck to toe was recommended in 26 studies, lesion only in four (three
of which were topical ivermectin and not specified
in seven studies. Full body application of topical
scabicides is recommended (1D). The effective
application of topical scabicides requires a private
setting where the clothes can be removed for application. This is not always practical or achievable
in overcrowded households and may limit the
effect of topical therapy.

Oral treatment vs. topical treatment—Moderate to highquality evidence supports the use of oral ivermectin or
topical permethrin for the treatment of scabies (1A) [32,
40–42].
A comparison of topical 5% permethrin with oral ivermectin in a high-quality RCT from India found lesion
count and pruritus significantly lower for permethrin at 1
week whilst clinical cure at 4 weeks was the same [40].
Moderate quality evidence from India reached similar
conclusions [32]. From Iran, low-quality evidence is provided from two studies that compared oral ivermectin
with topical permethrin and found superior symptom
relief with permethrin at 2 weeks, whilst clinical cure
was the same [41, 42]. There is moderate-high-quality
evidence that oral ivermectin achieved superior clinical
cure than topical lindane [43–45] or topical sulphur [46].
Comparisons of oral ivermectin with topical BB showed
discrepant results: no difference in clinical cure based on
high-quality RCT evidence from Vanuatu [47] whilst oral
ivermectin was superior for clinical cure in moderate
quality evidence from Senegal [48] and Nigeria [49].
Mass drug administration. There is moderate quality
evidence for MDA to control scabies in resource-limited
communities (1B) [50–53], with high-quality comparison RCTs needed to determine the best agent.
Moderate quality evidence for the population effect of
MDA for scabies on scabies and impetigo prevalence
was achieved using either topical permethrin or oral
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ivermectin (1B) [23, 54–56]. Oral ivermectin is superior
to topical permethrin and standard of care for community-wide use in children >5 years and non-pregnant
adults in isolated settings with high prevalence of scabies and impetigo (1B) [57]. High-quality studies conducted in mainland populations are required to
determine the effectiveness of the MDA approach in
highly mobile populations.
Scabies only—Low to moderate quality evidence from
four studies in Fiji [50], India [52, 53] and Tanzania [51]
assessed MDA impact on scabies prevalence only. Two
doses of oral ivermectin achieved a 95% reduction in scabies in India [52] whilst single dose ivermectin MDA was
not superior to BB in Fiji [50]. Ivermectin delivered in a
lymphatic filariasis MDA reported a 68–98% decline in
scabies [51]. When 25% BB was delivered in an MDA to
an Indian orphanage, cure was 100% at 6 weeks [53].
Scabies and impetigo—Permethrin MDA—Low-quality
evidence is provided from permethrin MDA’s, which
were all ecological in design with different populations
reviewed at baseline and follow-up. Four studies from
Panama [56] and remote Australian Aboriginal communities [23, 54, 55] showed a reduction in scabies and impetigo prevalence following MDA with 5% permethrin. The
first scabies MDA used permethrin in a remote Kuna
Indian population in Panama in 1986 and although interrupted by political tensions demonstrated a sustained
response [56]. The permethrin MDAs were combined
with impetigo treatment and broad-based community
skin programmes including surveillance, health promotion, home cleaning and retreatment of cases in Australia
[23, 54, 55].
Ivermectin vs. Permethrin MDA—Moderate quality evidence is provided from a cluster RCT where oral ivermectin and topical permethrin MDAs were compared
with standard case treatment with topical permethrin for
scabies in three Fijian island communities [57]. Ivermectin was superior at 12 months for scabies and impetigo [57].
Ivermectin MDA—Low-quality evidence is provided from
two studies that assessed the effect of oral ivermectin
MDA on scabies prevalence [58, 59]. In the Solomon
Islands, two doses of oral ivermectin reduced the prevalence of scabies at 3 years [59] and this was sustained at
a further follow-up 15 years later [60]. In contrast, an
oral ivermectin MDA delivered in a remote Australian
Aboriginal community did not show significant or sustained declines in scabies prevalence [58].

© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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Azithromycin MDA—Very low-quality evidence from an
azithromycin MDA for trachoma in a remote Australian
Aboriginal population reported impetigo reduction at 2–
3 weeks which returned to baseline at 6 months [61].
Scabies prevalence was unchanged [61].
Complimentary therapy. Moderate quality evidence that
cold cream can be used as an adjunct to topical sulphur
for scabies (2B) [62] .
In a Mexican orphanage RCT, topical 10% sulphur in
pork fat was compared with topical 10% sulphur in cold
cream with high rates of cure [62]. Preliminary data for
aloe vera for scabies treatment [63].
Communicable disease control and prevention. There is
low-quality evidence for treatment of household contacts
for the community control of scabies (2C) [64]. Treatment
of cases and contacts is recommended in scabies outbreaks
(2C), however, high-quality studies comparing treatments
during outbreaks are required.
Low-quality evidence for the treatment of household
contacts as the primary intervention for scabies control
from one cohort of Australian Aboriginal households
where a sixfold reduction in scabies in compliant households was found [64]. Fifteen other studies treated close
contacts, family members or the household as co-interventions for scabies, however, without a comparison group,
the effect cannot be reliably assessed. Moderate quality
evidence found that oral ivermectin halted a scabies outbreak amongst healthcare workers and patients in Peru
[65], and topical BB for cases and contacts with community education terminated an outbreak in Israel [66].
Environmental co-interventions. Although washing and
storage measures are unlikely to cause harm and should
be encouraged, high-quality studies assessing the clinical
effectiveness of washing clothing and bed linen, storage
of items in plastic bags, exposure to sunlight and household spraying are required before these measures can be
strongly recommended as adjuncts in the control of scabies. No studies used a control group to assess the effect
of environmental interventions for scabies. Twelve studies
included washing of clothing and bed linen [34, 39, 40,
43, 47–50, 53, 62–65], two studies included storage of
items in plastic bags [22, 65], four studies included
exposing items to direct sunlight [39, 47, 49, 53] and one
study included household spraying [66], as co-interventions (Table 2).
Crusted scabies. Moderate quality evidence supports oral
ivermectin with topical keratolytics and topical antiparasitics for crusted scabies (1B) [67, 68]. Comparative trials

are needed to explore more effective treatments. Patients
with crusted scabies require intensive supportive treatment (1B) [67, 68]. Coordinated case management in the
home may be of benefit (2C) [69].
Directed antimicrobial therapy. Moderate quality evidence from a prospective cohort study of Australian Aboriginal inpatients receiving oral ivermectin at days 0, 14
and 28 and daily topical permethrin alternating with keratolytic therapy (topical urea 10% and lactic acid 5%),
found 40% achieved complete cure at 4 weeks [68].
Standard treatment protocols. Moderate-quality evidence
from a retrospective study used a standard treatment protocol in Australian Aboriginal inpatients with crusted scabies achieving 55% without recurrence at 8 years [67].
Coordinated case management. Low-quality evidence
supports topical BB, regular keratolytics, moisturiser and
regular screening for new lesions in home-based case
management to prevent crusted scabies [69].
Fungal skin infections. Directed antimicrobial therapy. Tinea capitis—Moderate quality evidence for griseofulvin, terbinafine and fluconazole having similar
efficacy for tinea capitis (1B) [70–73]. Tinea capitis is
difficult to treat, takes several months and mycological
cure is challenging.
High-quality evidence of similar clinical and mycological cure was provided by a multicentre RCT from Guatemala, Chile, Costa Rica, USA and India comparing daily
oral fluconazole for 3 or 6 weeks with daily griseofulvin
[70]. Low-quality RCT evidence from Iran reported no
difference between daily fluconazole or daily griseofulvin
at 8 weeks [71]. Low-quality evidence from India found
griseofulvin twice daily, fluconazole weekly and terbinafine daily all performed similarly [72]. In addition, all used
ketoconazole 2% shampoo and prednisolone prescribed
for kerion [72]. From China, low-quality cluster RCT evidence confirmed griseofulvin daily for 4 weeks or terbinafine daily for 2–4 weeks performed similarly [73].
Tinea corporis—Low to moderate quality evidence for
topical sertaconazole, butenafine, miconazole or clotrimazole over other agents for tinea corporis (2C) [74–77].
Low-quality evidence that oral alternatives for tinea corporis are terbinafine or fluconazole (2C) [78]. Although
the systematic review on topical treatments for tinea corporis recommends topical terbinafine as a first-line agent
[17], no high-quality studies from resource-limited contexts were available to evaluate. Most included trials
came from dermatology outpatient clinics in India or
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Iran. Community setting, population level evidence is
needed for tinea corporis treatment.
Moderate quality RCT evidence from Iran confirmed similar clinical cure at 8 weeks for topical
butenafine compared with topical clotrimazole [76]
and similar cure rates at 4 weeks for topical miconazole and topical sertaconazole [74]. Moderate quality
RCT evidence from India found sertaconazole outperformed miconazole with 62% and 45% cured at
2 weeks respectively, P < 0.05 [75]. Low-quality evidence from India found topical clotrimazole and topical amorolfine were comparable [79] and that topical
sertaconazole was superior to topical butenafine [77].
Similarly, very low-quality pilot RCT evidence from
India found superiority of topical sertaconazole over
topical terbinafine or topical luliconazole for clinical
cure and symptom relief [80]. Very low-quality RCT
evidence also found no difference between topical sertaconazole and topical terbinafine [81] and that topical terbinafine and topical luliconazole could not be
differentiated [82]. Similarly, low-quality RCT evidence
from India found that daily oral terbinafine or weekly fluconazole achieved similar clinical cures [78] and topical
butenafine was no better than weekly fluconazole combined with topical Whitfield’s ointment (3% salicylic acid
and 6% benzoic acid) at 4 weeks [83]. Low-quality evidence from a prospective cohort of Australian Aboriginal
people with tinea corporis and tinea unguium found daily
oral terbinafine cured 32% [84].
Tinea unguium/onychomycosis—For tinea unguium,
moderate to high-quality evidence recommends oral terbinafine (1A) [85–87], with no added benefit of combination topical therapy in resource-limited settings (1B) [85,
88]. Surgical avulsion prior to treatment of onychomycosis is not recommended (2D) [88]. High-quality studies
assessing photodynamic therapy (PDT) regimens for tinea
unguium are required to determine the utility of this therapy in resource-limited settings.
High-quality RCT evidence from India trialled two different dosing regimens of terbinafine and showed no difference [85, 86]. Low-quality RCT evidence from Brazil
found monthly or second monthly dosing of oral terbinafine had similar outcomes [87] and photodynamic therapy
(PDT) every 15 days for 6 months was superior to
weekly oral fluconazole [89]. No additional benefit of
topical nail lacquer over oral terbinafine alone was found
in moderate quality evidence [85, 88].
Mass drug administration. No studies assessed the effect
of antifungal MDAs on the prevalence of fungal skin
infections.
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Complimentary/alternative therapy. Further studies are
needed to assess the role of aloe vera gel, as only very
low-quality evidence from one study is available [90].
Communicable disease prevention and control. No studies assessed the effect of communicable disease control
practices on fungal infections on which to base relevant
recommendations for resource-limited settings.
Hygiene practices. Daily soap use may be of benefit in
the treatment of tinea capitis and tinea corporis. This is
recommended in combination with anti-fungal treatment
(2C) [91].
From Tanzania, low-quality RCT evidence found
mycological cure at 2 months to be similar with either
daily washing with triclosan soap or placebo [91].
Infrastructure including high-quality water supply,
swimming pools and housing improvement for skin
infections. Water provision. An adequate supply of
water for washing and cleaning will reduce the burden of
impetigo and scabies (2C) [92]. From studies in remote
Australian Indigenous communities, the installation of
community swimming pools may assist in the prevention
of impetigo, along with other health benefits (2C)
[93–95]. No studies assessed the effect of quality
water supply or swimming pools on scabies or tinea
on which to base recommendations for resource-limited
settings.
Low-quality evidence from Panama found that when
unlimited, high-quality water was compared to a community with a limited water supply, declines in scabies
and impetigo incidence were reported [92]. Low-quality
evidence from three studies in Australian Aboriginal
communities found a small benefit following the installation of swimming pools for impetigo and skin infections [93–95].
Housing improvement programmes. Programmes to
improve housing may assist in the prevention and control
of skin infections in resource-limited populations (2C)
[96, 97].
Low-quality evidence from a housing intervention
evaluation of remote Australian Aboriginal communities, found construction of new, standardised housing
and the demolition of uninhabitable dwellings did not
change the prevalence of skin infections at 10 months
[96]. Low-quality evidence from a study that ran
for 12 years showed reductions in skin infections
following household improvements based on health
and safety priorities in a ‘survey and fix methodology.’[97]
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Discussion
This is the first systematic review to comprehensively
inform treatment, public health control and areas for
future research in the control of skin infections using evidence generated in and from settings where skin infection
burden is the highest. High-quality evidence for treatment
of the individual and community with scabies and for the
individual with impetigo is synthesised for inclusion into
evidence-based guidelines. Similarly, high-quality evidence
for comprehensively addressing scabies and impetigo concurrently is presented, with further studies needed to
determine the measurable benefit of additional interventions over treatment alone. The integration of oral antibiotics for treatment of impetigo, use of oral ivermectin or
topical permethrin MDA for scabies in endemic or outbreak settings and community education and health promotion activities in skin health programmes are
supported by the evidence and should form the basis of
skin control programmes when needed. Evidence gaps
include community control of dermatophyte infections
and targeted environmental health interventions to
improve skin health.
Progress towards the streamlined integration of data
collection on skin infections when planning MDAs for
other infections needs ongoing prioritisation. MDA for
trachoma and yaws with azithromycin [98–100] may also
reduce the burden of impetigo [61], whilst ivermectin
MDA for lymphatic filariasis [101] and scabies [57] will
reduce scabies and impetigo prevalence [61] as part of
the roadmap towards defeating neglected tropical diseases
[102]. This pragmatic, evidence-based strategy is now
being tested in larger populations with results awaited
(ACTRN12618000461291p) to inform whether community control of scabies will prevent severe skin infections.
For impetigo, duration of treatment, the role of topical
therapy and added benefit of comprehensive skin disease
control programmes over treatment alone are gaps in the
literature. Whilst 3 or 5 days of cotrimoxazole for impetigo treatment in resource-limited settings is effective [26],
more comparison studies are needed to optimise treatment duration and utility of cheap, widely available,
palatable alternative agents in high-burden contexts.
Cephalexin for up to 10 days remains in guidelines for
impetigo, yet this is lengthy, costly and may be impractical with no evidence supporting its use for impetigo in
high-burden contexts. Unlike developed settings where
topical mupirocin and fusidic acid are recommended
[16], there are currently no trials using topical antibiotics
for impetigo in high burden settings. Results from New
Zealand comparing topical antibiotics or antiseptics with
placebo are awaited [ACTRN1261000356460].

Knowledge gaps identified include the patient preference for agent to treat scabies, and the additional benefit
of comprehensive control programmes for scabies above
treatment alone. Topical permethrin has more rapid
reduction in symptoms [40, 42] but requires a private
space in which to apply the cream to the full body. Conversely, clinical response is slower, but ease of administration and overall community efficacy in MDA support
the use of ivermectin [57]. Future studies should address
the role of a second dose of ivermectin in asymptomatic
individuals as unhatched eggs are refractory to ivermectin
[103]. Moxidectin shows promise for future human scabies trials as it has a longer half-life and is ovicidal [104].
Most studies assessing antifungal treatments were from
dermatology OPD in middle-income country hospitals,
which limits the external validity to other resource-limited
settings. Studies assessing the effectiveness of topical and
oral (for severe disease) treatments of tinea in a range of
resource-limited populations would be of benefit to make
recommendations applicable to real life and uncontrolled
settings at the individual and population level. Future
integration of treatment of tinea into comprehensive skin
disease control programmes that address scabies and
impetigo may be a way forward.
Despite practical advantages, we found limited evidence for environmental interventions to control skin
infections. Although sound attempts to evaluate housing
programmes have been made [96, 97], we remain unable
to recommend small-scale environmental interventions
due to a lack of comparative studies. For example, no
studies compared household spraying with no intervention to eradicate the scabies mite. Similarly, there was no
evidence for hot washing of clothing compared to not
washing clothing. Although environmental measures are
unlikely to cause harm in combination with treatment of
the skin infection, research is needed to determine any
measurable benefit above standard treatment to inform
environmental health teams tasked with managing scabies
outbreaks, clinicians managing skin infections or governments and communities intending to include environmental policy recommendations in comprehensive skin health
programmes in endemic areas.
Although 1759 non-duplicate studies were found for
potential inclusion in this systematic review, most were
excluded prior to the final appraisal of 81 studies meeting
the full inclusion criteria (see Figure 1). This is the complete synthesis of available literature on these four skin
conditions. It is possible that restriction to English language publications or being unable to find the full text
publication has been a limitation in the scope of this,
although <30 full-text studies were excluded for this
reason.
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Conclusions
A summary of the evidence-based recommendations for
skin infections in high-burden contexts also highlights the
need for further rigorous, experimental studies to fill the
evidence gaps. Pragmatic, practical, high-quality, wellfunded RCTs are essential in the settings where the findings will have external validity if meaningful progress is
to be made towards reducing the gap in skin health outcomes between the rich and poor. Acknowledging that
RCTs may present ethical issues for some groups [105],
robust observational studies of appropriately funded public health interventions can be tested across large populations with designs that control for confounders and in
meaningful partnership with the communities under study
using participatory research methods.
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